SB1366 amends Virginia’s pharmacy compounding law to clarify when pharmacists may compound drugs and, most notably, to create an exception allowing compounded products to be distributed within a hospital or health system under common ownership when the products are administered only to patients within that system. The bill keeps the general rule that compounded drugs must be prepared pursuant to valid prescriptions or in anticipation of routine prescribing patterns, and it preserves existing labeling, recordkeeping, quality assurance, and supervision requirements.
The measure also restates and tightens several limits on compounding, including prohibitions on compounding unsafe withdrawn drugs, making essentially copies of commercially available products except in specified shortage or emergency situations, and producing inordinate amounts without a historical prescription pattern. It continues to allow limited distribution to veterinarians and to practitioners for office-based administration in emergency or other legally permitted circumstances, while requiring specific labels for products distributed for administration or animal use. The bill further requires sterile compounding pharmacies and nonresident pharmacies to notify the Board of Pharmacy if they intend to dispense sterile compounded products into Virginia.
In practical terms, the bill affects pharmacists, pharmacies, hospital systems, veterinarians, and prescribers by defining when compounded medications may move beyond the individual-patient prescription setting and by imposing detailed compliance obligations. It also reinforces the role of the Board of Pharmacy and related boards in regulating compounding standards, including USP-NF compliance, documentation, and inspection-ready records.
The overall sentiment around SB1366 appears strongly supportive and noncontroversial. It passed the Senate 40-0 and the House 96-0, and committee reports were unanimous, indicating broad bipartisan agreement. The lack of recorded opposition suggests the bill was viewed as a technical or clarifying update to existing compounding rules rather than a major policy dispute.
The main point of contention, insofar as the bill addresses one, is the balance between allowing needed flexibility for hospital and health-system compounding and preventing diversion, resale, or quasi-manufacturing of compounded drugs. The bill resolves that tension by permitting internal health-system distribution only when administration is limited to patients within the system, while maintaining restrictions on broader commercial distribution and on compounding of copies of commercially available drugs except in shortage or emergency circumstances.
SB1366 amends and reenacts Virginia Code § 54.1-3410.2, expanding and clarifying the statutory framework governing pharmacy compounding. It creates a specific exception for distribution within hospitals or health systems under common ownership when compounded drugs are administered only to patients within that system, while preserving restrictions on distribution to other pharmacies, commercial entities, and general resale. The bill also reinforces labeling, recordkeeping, quality assurance, and notification requirements for sterile compounding pharmacies, and it continues to regulate compounding by pharmacists and other authorized practitioners under Board oversight.
The bill’s sentiment was uniformly positive and largely procedural. It moved through committee and floor votes with unanimous support in both chambers, suggesting legislators viewed it as a practical clarification of compounding rules and a patient-care measure for hospitals and health systems rather than a controversial policy change.
The principal policy tension in SB1366 is between access and control: supporters of the exception for health-system distribution likely viewed it as necessary to support timely patient care inside integrated hospital systems, while the statute’s detailed limits reflect concern about compounded drugs being diverted into broader commercial channels or used to replicate mass-market products. The bill addresses those concerns by limiting the exception to administration within the hospital or health system and by preserving strict prohibitions on unauthorized distribution, copying of commercially available drugs, and compounding without a valid prescription basis.